Emvision Medical Devices
- Short interest
- 0.00%
- 0.00 pp 30d
- as of 27 July 2026
- Reported shorts
- 18
- Shares on issue
- 92.956M
Emvision Medical Devices (EMV) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $8.8MM (source: ASX (Markit))vs $5.6MM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 14 Oct 2026
- NPAT
- −$8.3Mvs −$9.8M (FY25)
- Yahoo Finance, as at 14 Oct 2026
- EPS (diluted)
- −$0.091T (source: Derived: trailing 12 months at year end)vs −$0.11 (FY25)
- Derived: trailing 12 months at year end, as at 14 Oct 2026
- Rev YoY
- +57.2%FY
- EPS YoY
- n/aTTM
- ASX (Markit)
- Derived: trailing 12 months at year end
Summary of Appendix 4E & Annual Report to 30 June 2026, 24 Aug 2026
EMVision Medical Devices reported FY26 revenue of $8.85 million, up 57% from the prior year, driven by higher grant income and R&D tax rebates. The net loss narrowed 15% to $8.32 million, reflecting increased investment in clinical trials and device manufacturing. No dividend was declared for the year.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 15 Oct 2026
- Gross margin
- n/a
- Operating margin
- −191.3%
- Net margin
- −94.0%
- FCF margin
- −72.0%
- ROE
- −66.4%
- ROA
- −43.1%
- FCF conversion
- n/a
- Net cash (excl. leases)
- $14.4M
- Net debt / EBITDA
- n/a
- Current ratio
- 5.5×
- Interest cover
- −83.2×
- Cash dividends paid / net profit
- n/a
- Market cap
- $144.1M
- P/E
- n/a
- P/B
- 9.1×
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance and ASX (Markit), as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $8.8MM (source: ASX (Markit)) | $5.6MM (source: ASX (Markit)) | $11.6MM (source: ASX (Markit)) | $7.1MM (source: ASX (Markit)) |
| Operating income | −$16.9M | −$13.9M | −$13.5M | −$10.9M |
| EBITDA | −$7.7M | −$7.9M | −$1.5M | −$3.5M |
| EBIT | −$8.1M | −$8.3M | −$1.9M | −$3.8M |
| Interest expense | $203.4K | $88.6K | $115.7K | $35.3K |
| Pretax income | −$8.3M | −$8.4M | −$2.0M | −$3.9M |
| Tax | $31.4K | $1.5M | $697.7K | $0 |
| NPAT | −$8.3M | −$9.8M | −$2.7M | −$3.9M |
| Net interest income | $287.7K | $488.1K | $225.5K | $84.3K |
| EPS basic | −$0.091T (source: Derived: trailing 12 months at year end) | −$0.11 | −$0.034 | −$0.050 |
| EPS diluted | −$0.091T (source: Derived: trailing 12 months at year end) | −$0.11 | −$0.034 | −$0.050 |
| Shares | 93.0M | 85.5M | 85.4M | 77.9M |
- ASX (Markit)
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Appendix 4E & Annual Report to 30 June 2026Annual Results24 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report15 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report13 Apr 2026via asx_announcements
- Half Yearly Report and AccountsHalf Year Results23 Feb 2026via asx_announcements
- Half Yearly PresentationHalf Year Results23 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report28 Jan 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report28 Oct 2025via asx_announcements
- Appendix 4E & Annual Report to 30 June 2025Annual Results28 Aug 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jul 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Apr 2025via asx_announcements
Showing 10 of 30 reports